Evidence map›Paper›PMID 36104316›Full record

ArticleBlood cancer journal2022

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma.

Peiyu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Xinyue Liang, Shanshan Yu, Weiling Xu, Yanping Ma, Xiaoqi Qin and 3 more

Abstract readLetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peiyu YangDepartment of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China.
Fan ZhouDepartment of Hematology and Oncology, Shanghai Jing'an District Zhabei Central Hospital, Shanghai, China.
Yujun DongDepartment of Hematology, Peking University First Hospital, Beijing, China.
Guangxun GaoDepartment of Hematology, Xijing Hospital, Air Force Medical University, Xi'an, Shanxi, China.
Hua XueDepartment of Hematology, the Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Xinyue LiangDepartment of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China.
Shanshan YuDepartment of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China.
Weiling XuDepartment of Radiology, the First Hospital of Jilin University, Changchun, Jilin, China.
Yanping MaDepartment Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xiaoqi QinDepartment Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Mengyao LiDepartment of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China.
Yun DaiLaboratory of Cancer Precision Medicine, the First Hospital of Jilin University, Changchun, Jilin, China. daiyun@jlu.edu.cn.ORCID 0000-0003-2285-0818
Fengyan JinDepartment of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China. fengyanjin@jlu.edu.cn.ORCID 0000-0003-2288-556X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaCohort StudiesHumansPrognosis

Identifiers

PMID36104316
PMCPMC9474810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.